| Autor: |
SHINYA TAKADA, YOSHIHIRO HOSOKAWA, KENGO UMEHARA, YUTA KIMURA, YUTA FUKAI, KARIN SHIKISHIMA, MITSUGU YAMAMOTO, HIDEKI MAEDA, NOBUMOTO TOMIOKA, KENICHI WATANABE, HIROKAZU HASHISHITA |
| Předmět: |
|
| Zdroj: |
In Vivo; Jan/Feb2024, Vol. 38 Issue 1, p500-505, 6p |
| Abstrakt: |
Background/Aim: Eribulin is an effective chemotherapeutic agent for advanced and metastatic breast cancer. However, severe neutropenia occurs in 30-40% of patients and interferes with the recommended treatment schedule. Neutropenia is a major cause of treatment interruptions, delays, or even relative dose reductions. This study aimed to examine the risk factors for severe neutropenia after eribulin treatment. Patients and Methods: We retrospectively evaluated 263 patients with metastatic breast cancer who had received eribulin therapy. Risk factors for severe neutropenia in the first cycle were evaluated. Results: Severe neutropenia in cycle 1 occurred in 50% of the patients. Multivariate analysis suggested six risk factors for severe neutropenia: low baseline neutrophil count and body mass index, high aspartate aminotransferase and bilirubin levels, creatinine clearance (CrCl) less than 50 ml/min, and eribulin dose of 1.4 mg/m². Conclusion: This is one of the few studies to simultaneously examine both hepatic and renal functions in relation to severe neutropenia induced by eribulin. We have provided important information to support the close monitoring of patients with these risk factors and subsequent dosage adjustments, if necessary. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
